Methods of using norfluoxetine
US7034059B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jun 28, 2002 |
| Grant date | Apr 25, 2006 |
| Priority date | — |
| Expiry date | Dec 26, 2022 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/56
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention encompasses methods of using racemic and enantiomerically pure norfluoxetine, as well as pharmaceutical compositions, pharmaceutical unit dosage forms, and kits comprising racemic and enantiomerically pure norfluoxetine. In particular, the invention encompasses a method of inhibiting or reducing the production of PGE2. The invention further encompasses a method of treating or preventing inflammation in a patient, as well as a method of treating or preventing a disease or disorder such as, but not limited to, autoimmune diseases, arthritis, neurologic diseases, inflammatory diseases, fibromyalgia, pain resulting from inflammation, neuropathic pain, and cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.